pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Sep 2·1 min read
save

ADA internal review refutes censorship and police involvement allegations after conference ejections

Sep 2, 2026·read at STAT ↗Neutral

The American Diabetes Association (ADA) completed an internal review following the removal of several members from its scientific sessions in New Orleans. The review concluded that there was no censorship of the editorial content and no involvement of local police in the incident.

The incident occurred three months earlier when ADA members were escorted out while distributing an editorial that criticized recent federal funding cuts. The members claimed the organization suppressed their views and called on police to enforce the removal.

ADA’s editor‑in‑chief, Steven Kahn, and other senior staff questioned the independence of the organization’s actions, prompting the review. The findings dismissed both the censorship and police involvement allegations and also rejected the notion that the ADA acted in response to the editorial’s substance.

STAT’s coverage notes that the ADA’s response aims to restore confidence in its governance and underscores ongoing tensions over funding and policy advocacy within the diabetes research community.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “HHS spins a tale of a would-be content creator child”

read at STAT ↗
1,137 words · retrieved Sep 2
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
RISINGUniversity of Washington
drugs
nirmatrelvir + ritonavir
topics
Psychiatry & CNS4Type 2 Diabetes4Immunology3AdComBi-specific T-cell engager (BiTE)CardiologyInfectious Disease

related stories

  • Aug 31A winner, a loser, and a mid-stage signal from a major cardiology research conferenceSTAT
  • Sep 8An administrative gap delays access to new pancreatic cancer treatmentSTAT
  • Sep 4Disabled workers at greater risk of losing health insuranceSTAT
  • Sep 3HHS flip-flops on disability lawsuitSTAT
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive